A Phase I Study to Evaluate the Safety and Tolerance of TQB3015 Tablets With Advanced Malignant Cancer
Latest Information Update: 02 Jan 2024
At a glance
- Drugs TQB 3015 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 26 Dec 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Dec 2023 New trial record